Evidence map›Paper›PMID 29720485›Full record

ReviewBlood2018

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Oussama Abla, Eric Jacobsen, Jennifer Picarsic, Zdenka Krenova, Ronald Jaffe, Jean-Francois Emile, Benjamin H Durham, Jorge Braier, Frédéric Charlotte, Jean Donadieu and 8 more

Registry-linked trialOpen access · bronzeAbstract readReviewConsensus Statement
In one paragraph

Review in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04943211 (Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose), which is not on this map. Cited by 304 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
304citing papers in PubMed, 3 pooled it
24.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04943211 phase3recruitingnot on this mapstarted 2021, after this paper: background citation

Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis

TypeinterventionalSponsorAnna RaciborskaRan2021 to 2027Enrolled150ConditionsHistiocytosisArmsfluorodeoxyglucose (18F-FDG)
3 · Its place in the literature

Who cites it

304 citing papers in PubMed, 3 syntheses or guidelines pooled it, 596 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. When Rosai-Dorfman meets autoimmunity.Internal and emergency medicine · 2026
    Article
  10. Head and neck rosai-dorfman disease: upper airway predominance in 42 patients.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  11. Article
  12. Article
  13. [Rosai-Dorfman Syndrome-a diverse clinical spectrum].Dermatologie (Heidelberg, Germany) · 2026
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

244 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 5 countries.

Oussama AblaDivision of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Eric JacobsenDana-Farber Cancer Institute, Boston, MA.
Jennifer PicarsicDepartment of Pathology, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Zdenka KrenovaPediatric Oncology Clinic, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Ronald JaffeDepartment of Pathology, Magee Women's Hospital of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Jean-Francois EmilePathology Department, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne, France.
Benjamin H DurhamDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Jorge BraierDepartment of Hematology, Oncology, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.
Frédéric CharlotteDepartment of Pathology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Jean DonadieuDepartment of Haematology, AP-HP, Trousseau Hospital, Paris, France.
Fleur Cohen-AubartDepartment of Internal Medicine, Paris VI University, Université Pierre et Marie Curie, Sorbonne Universités, Paris, France.
Carlos Rodriguez-GalindoSt. Jude Children's Research Hospital, Memphis, TN.
Carl AllenSection of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
James A WhitlockDivision of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Sheila WeitzmanDivision of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Kenneth L McClainSection of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Julien HarocheDepartment of Internal Medicine, Paris VI University, Université Pierre et Marie Curie, Sorbonne Universités, Paris, France.
Eli L DiamondDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY; and.
Hospital for Sick Children · CAMemorial Sloan Kettering Cancer Center · USPitié-Salpêtrière Hospital · FRUniversity of Pittsburgh · USAssistance Publique – Hôpitaux de Paris · FRBaylor College of Medicine · USDana-Farber Cancer Institute · USGarrahan Hospital · ARHôpital Ambroise-Paré · FRMasaryk University · CZSorbonne Université · FRSt. Jude Children's Research Hospital · USTexas Children's Hospital · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Cellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological MalignanciesK08CA218901 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DURHAM, BENJAMIN HEATH · 2018 to 2022
$1.0M
NCI NIH HHS K08 CA218901NCI NIH HHS L30 CA231804NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Rosai-Dorfman-Destombes disease (RDD) is a rare non-Langerhans cell histiocytosis characterized by accumulation of activated histiocytes within affected tissues. RDD, which now belongs to the R group of the 2016 revised histiocytosis classification, is a widely heterogeneous entity with a range of clinical phenotypes occurring in isolation or in association with autoimmune or malignant diseases. Recent studies have found

Indexed as

Adrenal Cortex HormonesBiopsyDisease ManagementGenetic Predisposition to DiseaseHistiocytesHistiocytosis, SinusHumansImmunotherapyMutationPractice Guidelines as TopicPrognosisRadiotherapyAdrenal Cortex Hormones

Identifiers

PMID29720485
PMCPMC6024636
OpenAlexW2802582740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.